SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Veradigm Inc. (MDRX) , forward earnings yield 6.46%. PEG 0.54 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.54); analyst target implies upside (+260.1%).
- Forward P/E 15.5
- PEG Ratio 0.54 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $16.17 (+260.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 57/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MDRX
Valuation Multiples
P/E (TTM)0.0
Forward P/E15.5
PEG Ratio0.54
Forward PEG0.54
P/B Ratio0.00
P/S Ratio0.98
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.67
Forward EPS (Est.)$0.29
Book Value / Share$0.00
Revenue / Share$4.56
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield6.46%
Dividend Yield0.00%
Analyst Target$16.17 (+260.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.59 |
$1.37B |
$-104.03M |
-7.6% |
| 2014 |
$-0.37 |
$1.38B |
$-66.45M |
-4.8% |
| 2015 |
$-0.01 |
$1.39B |
$-2.23M |
-0.2% |
| 2016 |
$-0.14 |
$1.55B |
$-25.65M |
-1.7% |
| 2017 |
$-1.09 |
$1.5B |
$-196.46M |
-13.1% |
| 2018 |
$2.04 |
$1.75B |
$363.74M |
20.8% |
| 2019 |
$-1.10 |
$1.63B |
$-182.18M |
-11.2% |
| 2020 |
$4.37 |
$1.5B |
$700.41M |
46.6% |
| 2021 |
$1.01 |
$1.5B |
$134.44M |
8.9% |
| 2022 |
$-0.67 |
$588.02M |
$-86.46M |
-14.7% |
